Andrea Fava
A5062420029- Systemic Lupus Erythematosus Research
- Systemic Sclerosis and Related Diseases
- Renal Diseases and Glomerulopathies
- Atherosclerosis and Cardiovascular Diseases
- T-cell and B-cell Immunology
- Inflammatory Myopathies and Dermatomyositis
- Monoclonal and Polyclonal Antibodies Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Liver Diseases and Immunity
- Viral Infections and Immunology Research
- Pericarditis and Cardiac Tamponade
- Hepatitis C virus research
- Reproductive System and Pregnancy
- Mast cells and histamine
- Immune cells in cancer
- Sympathectomy and Hyperhidrosis Treatments
- SARS-CoV-2 and COVID-19 Research
- Immune Cell Function and Interaction
- Inflammasome and immune disorders
- Autoimmune Bullous Skin Diseases
- Peripheral Neuropathies and Disorders
- Single-cell and spatial transcriptomics
- Dermatologic Treatments and Research
- Diabetes and associated disorders
- Autoimmune and Inflammatory Disorders Research
Johns Hopkins University
2016-2025
Johns Hopkins Medicine
2015-2024
Cedars-Sinai Medical Center
2024
Brigham and Women's Hospital
2024
Harvard University
2021-2024
Johns Hopkins Hospital
2024
Greater Baltimore Medical Center
2023
Center for Rheumatology
2022
Oklahoma Medical Research Foundation
2021
Broad Institute
2021
Autoimmune diseases are thought to be initiated by exposures foreign antigens that cross-react with endogenous molecules. Scleroderma is an autoimmune connective tissue disease in which patients make antibodies a limited group of autoantigens, including RPC1, encoded the POLR3A gene. As scleroderma and against RPC1 at increased risk for cancer, we hypothesized "foreign" this somatically mutated genes patients' incipient cancers. Studying cancers from patients, found genetic alterations locus...
Lupus nephritis, one of the most serious manifestations systemic lupus erythematosus (SLE), has a heterogeneous clinical and pathological presentation. For example, proliferative nephritis identifies more aggressive disease class that requires immunosuppression. However, current classification system relies on static appearance histopathological morphology, which does not capture differences in inflammatory response. Therefore, biomarker grounded biology is needed order to understand...
Objective Current lupus nephritis (LN) treatments are effective in only 30% of patients, emphasizing the need for novel therapeutic strategies. We undertook this study to develop mechanistic hypotheses and explore biomarkers by analyzing longitudinal urinary proteomic profiles LN patients undergoing treatment. Methods quantified 1,000 proteins 30 with at time diagnostic renal biopsy after 3, 6, 12 months. The molecular pathways detected urine proteome were then analyzed respect baseline...
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with dramatic sex bias, affecting 9-times more women than men. Activation of toll-like receptor 7 (TLR7) by self-RNA central pathogenic process leading to aberrant production type-I interferon (IFN) in SLE, but the specific RNA molecules that serve as TLR7 ligands have not been defined. We therefore sought identify female-specific endogenous RNAs containing canonical stimulatory motifs. By leveraging gene expression data and...
Lupus nephritis (LN) is a pathologically heterogenous autoimmune disease linked to end-stage kidney and mortality. Better therapeutic strategies are needed as only 30%-40% of patients completely respond treatment. Noninvasive biomarkers intrarenal inflammation may guide more precise approaches. Because urine collects the byproducts inflammation, we studied proteomic profiles 225 with LN (573 samples) in longitudinal Accelerating Medicines Partnership RA/SLE cohort. Urinary...
Abstract Background Leveraging the Accelerating Medicines Partnership (AMP) Lupus Nephritis (LN) dataset, we evaluated longitudinal patterns, rates, and predictors of response to standard-of-care therapy in patients with lupus nephritis. Methods Patients from US academic medical centers class III, IV, and/or V LN a baseline urine protein/creatinine (UPCR) ratio ≥ 1.0 ( n = 180) were eligible for this analysis. Complete (CR) required following: (1) UPCR < 0.5; (2) normal serum creatinine...
The risk of COVID-19 infection is increased in patients with systemic lupus erythematosus (SLE) versus those without SLE. Some immunosuppressive medications increase and decrease the efficacy vaccination. Consensus documents have suggested management strategies for handling to vaccine efficacy, but benefit such has not been proven. current study was undertaken determine effect drugs on response
Lupus nephritis (LN) is a frequent manifestation of systemic lupus erythematosus, and fewer than half patients achieve complete renal response with standard immunosuppressants. Identifying non-invasive, blood-based pathologic immune alterations associated injury could aid therapeutic decisions. Here, we used mass cytometry immunophenotyping peripheral blood mononuclear cells in 145 biopsy-proven LN 40 healthy controls to evaluate the heterogeneity activation identify correlates parameters...
Abstract Viral infections have been associated with autoimmune connective tissue diseases. To evaluate whether active infection by Epstein–Barr virus (EBV), cytomegalovirus (CMV), human herpesvirus (HHV)‐6, ‐7, ‐8, as well parvovirus B19 (B19V) occur in patients diseases, viral DNA loads were assessed paired samples of serum and peripheral blood mononuclear cells (PBMCs) 115 affected different disorders, including systemic sclerosis, systemic, discoid lupus erythematosus, rheumatoid...
The RhoA/Rho kinase pathway plays a pivotal role in cold-induced vasoconstriction, vascular smooth muscle cells function, and homeostasis. This study evaluates the efficacy of fasudil, inhibitor, to reverse vasospasm patients with Raynaud's phenomenon (RP) secondary systemic sclerosis (SSc; scleroderma).This is single-center, double-blind, placebo-controlled, randomized, 3-period crossover oral fasudil (40 mg or 80 mg) placebo administered 2 hours before standardized cold challenge. fall...
To assess the efficacy of anifrolumab, a type-1 interferon receptor subunit-1 monoclonal antibody, in treating refractory cutaneous lupus erythematosus (CLE) and non-specific mucocutaneous manifestations patients with systemic (SLE).
Autoantibodies are a hallmark of lupus nephritis (LN), but their association with LN classes and treatment response not adequately known. In this study, we quantified circulating autoantibodies in the Accelerating Medicines Partnership longitudinal cohort to identify serological biomarkers histologic classification how these change over time based on response.
Importance Pericarditis is the most common cardiac manifestation of systemic lupus erythematosus (SLE) and known to recur among patients. However, prevalence risk factors associated with recurrent pericarditis in patients SLE were unknown. Objective To investigate frequency recurrence SLE. Design, Setting, Participants This cohort study was a retrospective analysis well-characterized, single-center prospective diverse group treated at tertiary medical center enrolled between 1988 2023....
Objective The objective is to provide evidence‐based and expert guidance for the screening, treatment, management of lupus nephritis. Methods Core Team developed clinical questions nephritis using PICO format (population, intervention, comparator, outcome). Systematic literature reviews were completed each question, Grading Recommendations Assessment, Development Evaluation (GRADE) methodology was used assess quality evidence formulate recommendations. Voting Panel achieved a consensus ≥70%...
Scleroderma is an antigen-driven T cell-mediated autoimmune disease. Presence of anti-topoisomerase-I antibodies associated with pulmonary fibrosis and predicts increased mortality. Characterization autoreactive lymphocytes may shed light on disease pathogenesis serve as a biomarker for activity. Here, we aimed to quantify functionally characterize circulating topoisomerase I (topo-I)-specific CD4+ cells define their association presence progression interstitial lung (ILD) in patients...
Objective Bone resorption of distal phalanges, or acroosteolysis (AO), can develop in patients with systemic sclerosis (SSc), causing pain and functional limitation. This study was undertaken to investigate whether AO may be associated abnormal osteoclastogenesis SSc hypoxia involved this process. Methods Peripheral blood mononuclear cells (PBMCs) obtained from 26 (11 15 without AO) 14 healthy controls were cultured the presence RANKL macrophage colony‐stimulating factor for 9 days....
Delayed detection of LN associates with worse outcomes. There are conflicting recommendations regarding a threshold level proteinuria at which biopsy will likely yield actionable management. This study addressed the association urine protein:creatinine ratios (UPCR) clinical characteristics and investigated incidence proliferative membranous histology in patients UPCR between 0.5 1.A total 275 SLE (113 first biopsy, 162 repeat) were enrolled multicentre multi-ethnic/racial Accelerating...
Proteolysis of autoantigens can alter normal MHC class II antigen processing and has been implicated in the induction autoimmune diseases. Many are substrates for protease granzyme B (GrB), but mechanistic significance this association is unknown. Peptidylarginine deiminase 4 (PAD4) a frequent target autoantibodies patients with rheumatoid arthritis (RA) substrate GrB. RA strongly associated specific alleles, elevated levels GrB PAD4 found joints patients, suggesting that may presentation by...
Treatment response in lupus nephritis (LN) is defined based on proteinuria, yet protocol kidney biopsy studies have shown that patients with can active the absence of proteinuria. Using estimated glomerular filtration rate (eGFR) trajectories, we characterised early chronic disease LN and examined whether certain continue to accrue renal damage despite proteinuric response.
Abstract Objective Lupus nephritis (LN) can occur as an isolated component of disease activity or be accompanied by diverse extrarenal manifestations. Whether renal is sufficient to decrease health-related quality life (HRQOL) remains unknown. This study compared Patient-Reported Outcomes Measurement Information System 29-Item (PROMIS-29) scores in LN patients with those symptoms evaluate the burden on HRQOL and inform future clinical trials incorporating outcomes. Methods A total 181...
To evaluate urinary activated leucocyte cell adhesion molecule (ALCAM) and CD6 as predictors of lupus nephritis (LN) progression or disease resolution across a 1-year study.
Objective Scleromyxedema (SMX) is a rare systemic sclerosis mimic that often responds to intravenous immunoglobulin (IVIG) therapy, yet the resulting clinical and biochemical changes have not been well characterized. To better understand pathogenesis of disease efficacy IVIG, we sought explore whether IVIG would introduce measurable biologic effect corresponding with improvement. Methods Fifteen patients SMX were recruited for study. Clinical information peripheral blood mononuclear cells...